AR049302A1 - Modulacion de receptores activados por proliferador de peroxisoma - Google Patents

Modulacion de receptores activados por proliferador de peroxisoma

Info

Publication number
AR049302A1
AR049302A1 ARP050102409A ARP050102409A AR049302A1 AR 049302 A1 AR049302 A1 AR 049302A1 AR P050102409 A ARP050102409 A AR P050102409A AR P050102409 A ARP050102409 A AR P050102409A AR 049302 A1 AR049302 A1 AR 049302A1
Authority
AR
Argentina
Prior art keywords
modulation
receptors activated
reductase
subject
effective amount
Prior art date
Application number
ARP050102409A
Other languages
English (en)
Original Assignee
Abgenomics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abgenomics Corp filed Critical Abgenomics Corp
Publication of AR049302A1 publication Critical patent/AR049302A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)

Abstract

Un método para el tratamiento de una enfermedad relacionada con receptores activados por proliferador de peroxisoma (PPAR), que comprende administrar a un sujeto en necesida del mismo una cantidad efectiva de un modulador de 15-cetoprostaglandin- delta13-reductasa. También se describen métodos para la identificacion de un compuesto para inhibir la actividad de la reductasa y para reducir niveles de glucosa en sangre mediante la administracion a un sujeto de una cantidad efectiva de un inhibidor de reductasa.
ARP050102409A 2004-06-10 2005-06-13 Modulacion de receptores activados por proliferador de peroxisoma AR049302A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65146904P 2004-06-10 2004-06-10
US66447305P 2005-03-22 2005-03-22

Publications (1)

Publication Number Publication Date
AR049302A1 true AR049302A1 (es) 2006-07-12

Family

ID=34942397

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050102409A AR049302A1 (es) 2004-06-10 2005-06-13 Modulacion de receptores activados por proliferador de peroxisoma

Country Status (11)

Country Link
US (3) US20060003410A1 (es)
EP (2) EP1611887A3 (es)
JP (2) JP2005348733A (es)
KR (2) KR20060046420A (es)
AR (1) AR049302A1 (es)
AU (2) AU2005202503A1 (es)
CA (2) CA2507738A1 (es)
IL (1) IL169110A0 (es)
NZ (2) NZ540675A (es)
SG (4) SG138605A1 (es)
TW (2) TW200605868A (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7685530B2 (en) * 2005-06-10 2010-03-23 T-Mobile Usa, Inc. Preferred contact group centric interface
WO2006135084A1 (ja) * 2005-06-14 2006-12-21 Kurume University 脂肪性肝炎または脂肪肝の予防または治療薬
US20090124688A1 (en) * 2006-01-06 2009-05-14 Rong-Hwa Lin Prostaglandin reductase inhibitors
US20150184284A1 (en) 2012-06-29 2015-07-02 Oerlikon Advanced Technologies Ag Method of coating by pulsed bipolar sputtering
JP6314142B2 (ja) * 2012-09-21 2018-04-18 レオキシン ディスカバリーズ グループ，インコーポレイテッド 液体を電気分解するためのセル
TWI511736B (zh) * 2013-11-18 2015-12-11 Nat Univ Chiayi Peach Extract and Its Use and Extraction

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
WO1997018808A1 (en) * 1995-11-17 1997-05-29 Pharmacia & Upjohn Company 4-hydroxycoumarin-3-carboxamides for the treatment of diabetes mellitus
JPH10167964A (ja) * 1996-12-05 1998-06-23 Otsuka Pharmaceut Factory Inc クマリン誘導体を含有する医薬組成物
US6001311A (en) 1997-02-05 1999-12-14 Protogene Laboratories, Inc. Apparatus for diverse chemical synthesis using two-dimensional array
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AU776150B2 (en) 1999-01-28 2004-08-26 Medical College Of Georgia Research Institute, Inc. Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA
DE19956568A1 (de) * 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
CN1375004A (zh) * 1999-04-21 2002-10-16 惠氏公司 抑制多核苷酸序列的功能的方法和组合物
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
CN1329012A (zh) * 2000-06-21 2002-01-02 上海博德基因开发有限公司 一种新的多肽——烟酰胺腺嘌呤脱氧二核苷酸依赖性白三烯b412－羟基脱氢酶36和编码这种多肽的多核甘酸
CA2423701A1 (en) * 2000-09-29 2002-04-04 Incyte Genomics, Inc. Oxidoreductases
WO2002040656A2 (en) * 2000-11-14 2002-05-23 Millennium Pharmaceuticals, Inc. 47476, 67210, 49875, 46842, 33201, 83378, 84233, 64708, 85041, and 84234, novel human guanine nucleotide dissociation stimulator, glycosyltransferase, dead type helicase, centaurin, dehydrogenase/reductase, and metal transporter family members and uses thereof
IL160964A0 (en) * 2001-10-11 2004-08-31 Kaneka Corp Peroxisome proliferator activated receptor ligand and process for producing the same
EP1620573A4 (en) * 2003-04-15 2006-12-20 Avalon Pharmaceuticals DETERMINATION OF CANCER-ASSOCIATED GENES AND THERAPEUTIC OBJECTS USING MOLECULAR CYTOGENETIC PROCEDURES

Also Published As

Publication number Publication date
TW200603824A (en) 2006-02-01
NZ540676A (en) 2006-05-26
EP1612266A2 (en) 2006-01-04
CA2507847A1 (en) 2005-12-10
CA2507738A1 (en) 2005-12-10
EP1612266A3 (en) 2006-02-08
SG118360A1 (en) 2006-01-27
TW200605868A (en) 2006-02-16
US20060040876A1 (en) 2006-02-23
JP2005350472A (ja) 2005-12-22
JP2005348733A (ja) 2005-12-22
SG118362A1 (en) 2006-01-27
US20080086000A1 (en) 2008-04-10
KR20060046421A (ko) 2006-05-17
AU2005202503A1 (en) 2006-01-05
AU2005202505A1 (en) 2006-01-05
KR20060046420A (ko) 2006-05-17
EP1611887A3 (en) 2006-02-08
EP1611887A2 (en) 2006-01-04
SG138605A1 (en) 2008-01-28
IL169110A0 (en) 2007-07-04
NZ540675A (en) 2007-12-21
US20060003410A1 (en) 2006-01-05
SG138604A1 (en) 2008-01-28

Similar Documents

Publication Publication Date Title
AR054909A1 (es) Modulacion de los receptores activados por el proliferador de peroxisomas
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
UY32032A (es) "2-[1-sustituido-1h-pirazolo[3,4-d]pirimidin-4-il](io, oxi o amino)-n-(heteroaril)alcanamidas"
AR049302A1 (es) Modulacion de receptores activados por proliferador de peroxisoma
UY29274A1 (es) Composicion farmaceutica para tratar la hipertension, que comprende telmisartano e hidroclorotiazida
AR054566A1 (es) Tratamientoombinado de los tumores que expresan el her
ES2422739T3 (es) Composición para el diagnóstico, prevención o tratamiento de enfermedades relacionadas con células que expresan IL-8 o GRO-, que comprende MSC de UCB
ECSP066392A (es)
DOP2011000188A (es) Compuestos de tiazolopiridinas moduladores de sirtuina
PE20050469A1 (es) Modulacion de la expresion de eif4e
CL2008000594A1 (es) Uso de compuestos derivados de heterociclos; composicion farmaceutica que comprende a dichos compuestos y otros agentes activos; y su uso para tratar diabetes, enfermedad arterial coronaria entre otras enfermedades.
NO20084919L (no) Oksadiazolidindionforbindelse
GT200500158A (es) Derivados de amino-5,5-difenilimidazolona para la inhibicion de la b-secretasa
PA8637201A1 (es) Difenilimidazopirimidina e-imidazol aminas como inhibidores de la b-secretasa
AR109263A2 (es) Composición que comprende moxidectina
AR042705A1 (es) Derivados de pirazol modulador de ppar
NI200800169A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor
CY1116938T1 (el) Αναπληρωτικη θεραπεια της ασθενειας huntington και αλλων ασθενειων πολυγλουταμiνης
ES2552654T3 (es) Uso de LCAT para tratar la anemia y la disfunción de los glóbulos rojos
CO6311083A2 (es) 4-((1r,3s)-6-cloro-3-fenilindan-1-il)-1,2,2-trimetilpiperazina para el tratamiento de la disfunción cognitiva
UY30675A1 (es) Metodos para el tratamiento de la depresion
TW200640467A (en) Compounds and uses thereof
ECSP077843A (es) Tratamiento o prevención del prurito
AR060312A1 (es) Metodos para regular renalasa (monoamina oxidasa c)
UY28006A1 (es) Agonistas ppar quirales

Legal Events

Date Code Title Description
FA Abandonment or withdrawal